Eisai, Biogen Alzheimer's Drug Leqembi Would Cost US Medicare up to $5 Billion a Year, Study Finds More Reuters FILE PHOTO: The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout...
Concerns were raised about the financial burden of new plaque-targeting Alzheimer’s drugs like Leqembi on Medicare, given that the cost of a year’s supply of the drug amounts to around $26,500 for biweekly intravenous administrations. ...
collaboration with Eisai, a major Chinese medical insurance company has developed and launched a healthcare insurance plan specifically for AD including partial coverage of the drug cost. Through these efforts, Eisai is committed to promoting the early detection, diagnosis, and treatment of AD in...
There is a wealth of research on Alzheimer's, but it has been notoriously difficult to treat. Multiple drugs designed to target the disease havefailedin trials. The sheer cost and length of that research further impede drug development. And in recent years, scientists haveignited a debateo...
Benefit also matters to insurers like Medicare that pay for these very expensive drugs.Eisai has priced Leqembiat $26,500 per year. This cost, together with the challenging language of benefit, has instigatedsharp debates over cost effectiveness. Medicare, though forbidden to use...